Rigel Pharmaceuticals (RIGL) EBT Margin (2010 - 2026)

Rigel Pharmaceuticals' EBT Margin history runs 16 years deep, the most recent figure standing at 19.82% for Q1 2026.

• In Q1 2026, EBT Margin fell 176.0% year-over-year to 19.82%; the TTM figure through Mar 2026 stood at 40.69% (up 2192.0% YoY), while the FY2025 annual figure was 41.4%, up 3115.0% from the prior year.
• EBT Margin for Q1 2026 stood at 19.82%, down from 32.54% in the prior quarter.
• The five-year high for EBT Margin was 58.99% in Q2 2025, with the low at 164.0% in Q1 2022.
• The 5-year median for EBT Margin is 0.17% (2023), against an average of 11.7%.
• Peak annual rise in EBT Margin reached 11396 bps in 2022, while the deepest fall reached 21494 bps in 2022.
• Rigel Pharmaceuticals' EBT Margin stood at 2.73% in 2022, then plunged by 106 bps to 0.17% in 2023, then soared by 15607 bps to 26.43% in 2024, then increased by 23 bps to 32.54% in 2025, then tumbled by 39 bps to 19.82% in 2026.
• Business Quant data shows RIGL's EBT Margin at 19.82% in Q1 2026, 32.54% in Q4 2025, and 39.76% in Q3 2025.